Serum tumor marker levels might have little significance in evaluating neoadjuvant treatment response in locally advanced breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 11, 2015, Pages 4603-4608

  Wang, Yu Jie ^a   Huang, Xiao Yan ^a   Mo, Miao ^a   Li, Jian Wei ^a   Jia, Xiao Qing ^a   Shao, Zhi Min ^a   Shen, Zhen Zhou ^a   Wu, Jiong ^a   Liu, Guang Yu ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Neoadjuvant chemotherapy; PCR; Prognostic function; Serum tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; BLOOD; BREAST NEOPLASMS; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; ROC CURVE; YOUNG ADULT;

EID: 84936971002     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.11.4603     Document Type: Article

References (26)

1. Al-Azawi D, Kelly G, Myers E, et al (2006). CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer, 6, 220.
2. Cho JH, Park JM, Park HS, et al (2013). Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. J Surg Oncol, 108, 531-6.
3. Cortazar P, Zhang L, Untch M, et al (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 384, 164-72.
4. Coudert B, Pierga JY, Mouret-Reynier MA, et al (2014). Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncol, 15, 1493-502.
5. de Ronde JJ, Bonder MJ, Lips EH, et al (2014). Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypes. PLoS One, 9, 88551.
6. Denkert C, Loibl S, Muller BM, et al (2013). Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol, 24, 2786-93.
7. Duffy MJ (2006). Serum tumor markers in breast cancer: are they of clinical value? Clin Chem, 52, 345-51.
8. Duffy MJ (2007). Role of tumor markers in patients with solid cancers: A critical review. Eur J Intern Med, 18, 175-84.
9. th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4.
10. Hatt M, Groheux D, Martineau A, et al (2013). Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med, 54, 341-9.
11. Houssami N, Macaskill P, von Minckwitz G, et al (2012). Metaanalysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer, 48, 3342-54.
12. Khatcheressian JL, Hurley P, Bantug E, et al (2013). Breast cancer follow-up and management after primary treatment: American society of clinical oncology clinical practice guideline update. J Clin Oncol, 31, 961-5.
13. Koolen BB, Pengel KE, Wesseling J, et al (2014). Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imag, 41, 32-40.
14. Lee JS, Park S, Park JM, et al (2013). Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol, 24, 1225-31.
15. Lips EH, Mulder L, de Ronde JJ, et al (2013). Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat, 140, 63-71.
16. Liu Y, Huang X, Bi R, et al (2014). Similar prognoses for invasive micropapillary breast carcinoma and pure invasive ductal carcinoma: a retrospectively matched cohort study in China. PLoS One, 9, 106564.
17. Park BW, Oh JW, Kim JH, et al (2008). Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol, 19, 675-81.
18. Ramsey SD, Henry NL, Gralow JR, et al (2015). Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol, 33, 149-55.
19. Schnipper LE, Smith TJ, Raghavan D, et al (2012). American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol, 30, 1715-24.
20. Shin HC, Han W, Moon HG, et al (2013). Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. Ann Surg Oncol, 20, 2582-9.
21. Takada M, Sugimoto M, Ohno S, et al (2012). Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique. Breast Cancer Res Treat, 134, 661-70.
22. Wolff AC, Hammond ME, Hicks DG, et al (2014). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med, 138, 241-56.
23. Wolmark N, Wang J, Mamounas E, et al (2001). Preoperative chemotherapy in patients with operable breast cancer: nineyear results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr, 96-102.
24. Yerushalmi R, Tyldesley S, Kennecke H, et al (2012). Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol, 23, 338-45.
25. Yoshioka T, Hosoda M, Yamamoto M, et al (2015). Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer, 22, 185-91.
26. Zhang SJ, Hu Y, Qian HL, et al (2013). Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev, 14, 3937-40.